Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 4, 2006, Pages 293-295

  Antony, Suresh J ^a  

^a Paul L Foster School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN;

ARTICLE; CASE REPORT; DRUG COMBINATION; FEMALE; HUMAN; JOINT PROSTHESIS; MALE; MIDDLE AGED; PENICILLIN RESISTANCE; POSTOPERATIVE PERIOD; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINT PROSTHESIS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; POSTOPERATIVE PERIOD; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 33745038340     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500372697     Document Type: Article

References (20)

1. Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003;36:1157-611.
2. Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trends in the treatment of orthopedic prosthetic infections. J Antimicrob Chemother 2004;53:127-9 (Pubitemid 38239937)
3. Darley ES, MacGowan AP. Antibiotic treatment of Grampositive bone and joint infections. J Antimicrob Chemother 2004;53:928-35 (Pubitemid 38811422)
4. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency Use Study Group. J Antimicrob Chemother 2000;46:775-84
5. Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, Raoult D. Ambulatory treatment of multidrugresistant Staphylococcus-infected orthopedic implants with high-dose oral cotrimoxazole (trimethoprim- sulfamethoxazole). Antimicrob Agents Chemother 1998;42:3086-91 (Pubitemid 28553722)
6. Antony SJ, az-Vasquez E, Stratton C. Clinical experience with linezolid in the treatment of resistant Gram-positive infections. J Natl Med Assoc 2001;93:386-91
7. Daptomycin (Cubicin) for skin and soft tissue infections. Med Lett Drugs Ther 2004;46:11-2
8. Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003;52:89-95 (Pubitemid 36850091)
9. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33: 689-92 (Pubitemid 19120013)
10. Fantin B, Carbon C. In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother 1992; 36:907-12
11. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign Body Infection (FBI) Study Group. JAMA 1998; 279:1537-41 (Pubitemid 28233008)
12. Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40 (Pubitemid 27116419)
13. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48: 2871-5 (Pubitemid 38989149)
14. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53:530-2 (Pubitemid 38380256)
15. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of betalactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991 January;35(1):92-8
16. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003 May;47(5):1714-8 (Pubitemid 36548559)
17. Palmer SM, Rybak MJ. Pharmacodynamics of once-or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 1996 March;40(3):701-5 (Pubitemid 26071538)
18. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 2004 October; 48(10):4016-9 (Pubitemid 39304638)
19. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003 August;47(8):2538-44 (Pubitemid 36919456)
20. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 2004 March 15;38(6):864-70 (Pubitemid 38387236)